Delisting risk
CELZ · NASDAQ · Biotechnology

Creative Medical Technology

Develops regenerative cell therapies for pain and diabetes alongside physician-use procedure kits.

$1.13
After-hours close−0.03 (−2.42%)
At close$1.16(+1.58%)
DateEstimateReportedSurprise
Nov 2026−$0.24
Aug 2026−$0.39−$0.41−5.1%
May 2026−$0.39−$0.38+2.6%
Mar 2026−$0.37−$0.80−116.2%
Nov 2025−$0.48−$0.480.0%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Dec 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Apr 2020
Nov 2019
Aug 2019
Jun 2019
May 2019
Nov 2018
Aug 2018
Aug 2018
Mar 2018
Nov 2017
Aug 2017
May 2017
Feb 2017
Nov 2016
Aug 2016
May 2016
Apr 2016
Nov 2015
Aug 2015
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 6, 2026−$0.24
Aug 7, 2026−$0.39−$0.41−5.1%
May 8, 2026−$0.39−$0.38+2.6%
Mar 20, 2026−$0.37−$0.80−116.2%$3.0K$3.0K0.0%
Nov 7, 2025−$0.48−$0.480.0%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Aug 8, 2025
May 9, 2025
Mar 14, 2025
Nov 8, 2024
Aug 9, 2024
May 10, 2024
Mar 22, 2024
Nov 14, 2023
Aug 11, 2023
May 12, 2023
Mar 31, 2023
Nov 10, 2022
Aug 12, 2022
May 13, 2022
Mar 30, 2022
Dec 6, 2021
Aug 16, 2021
May 17, 2021
Mar 17, 2021
Nov 13, 2020
Aug 14, 2020
May 15, 2020
Apr 6, 2020
Nov 14, 2019
Aug 13, 2019
Jun 28, 2019
May 20, 2019
Nov 14, 2018
Aug 14, 2018
Aug 2, 2018
Mar 29, 2018
Nov 13, 2017
Aug 14, 2017
May 10, 2017
Feb 13, 2017
Nov 10, 2016
Aug 19, 2016
May 13, 2016
Apr 14, 2016
Nov 9, 2015
Aug 13, 2015